Gene · 4739
NIH grants1,451
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 1,451
Download this page as JSON| Grant | Title | NEDD9 papers | Newest fiscal year |
|---|---|---|---|
| R01AI185016 | Defining CasL as an Orchestrator of T cell Migration | 1 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 1 | 2025 |
| R01AR062173 | The IL-23/IL-17 Axis in Inflammatory Arthritis | 1 | 2025 |
| R01AR072304 | Therapeutic strategies for treatment of giant congenital melanocytic nevi | 1 | 2025 |
| R01CA074305 | Chemical Approaches to Cell Signaling Enzymes | 1 | 2025 |
| R01CA132946 | Genomics of AML Prognosis | 1 | 2025 |
| R01CA140337 | Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation | 1 | 2025 |
| R01CA148761 | Therapeutic Targeting of Breast Cancer Tumor Initiating Cells | 1 | 2025 |
| R01CA220468 | Bottlebrush polymer prodrugs for targeted delivery of combination therapies and in vivo imaging of pharmacological response | 1 | 2025 |
| R01CA250110 | Targeting Posttranslational Modifications in Breast Carcinogenesis | 1 | 2025 |
| R01CA251555 | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | 1 | 2025 |
| R01CA258765 | Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy | 1 | 2025 |
| R01CA258857 | Targeting posttranslational modifications of CD73 in TNBCs | 1 | 2025 |
| R01CA262577 | Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | 1 | 2025 |
| R01CA266389 | Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies | 1 | 2025 |
| R01DE016937 | A Foundation for the Oral Microbiome and Metagenome | 1 | 2025 |
| R01DE031274 | Impact of Saccharibacteria and their bacterial hosts in Periodontal and Inflammatory Diseases | 1 | 2025 |
| R01DK039520 | New Mechanisms and Functions of the Pro/N Degron and Arg/N-Degron Pathways | 1 | 2025 |
| R01DK057993 | Pathophysiology of Biliary Disease | 1 | 2025 |
| R01DK062370 | Identifying Genes for Type 2 Diabetes: FUSION | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4739/grants?page=7